Drawing for RE-1

USPTO serial 98852859

RE-1

Reviewed by CopyMark Law Group

Status 653
Filing date
Status date
Registration date
—
Examiner
FRIZALONE, SARAH O
Law office
TMO LAW OFFICE 112

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with RE-1?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Steven M. Evans

Steven M. Evans Chicago IP Law1750 W. Ogden Ave., #2405Naperville, IL 60567United States

Goods and services

ClassDescriptionStatusFirst use
005Dietary supplements; Mineral supplements; Nutritional supplements; Vitamin supplementsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 30, 2026ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Aug 14, 2026GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Aug 14, 2026GNSLLETTER OF SUSPENSION E-MAILED—
Aug 14, 2026CNSLSUSPENSION LETTER WRITTEN—
Jul 18, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 18, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 18, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 30, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 30, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 30, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 20, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 20, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 20, 2026ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
May 20, 2026EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
May 20, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 20, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 20, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 8, 2026GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
May 8, 2026GNSIINQUIRY TO SUSPENSION E-MAILED—
May 8, 2026CNSISUSPENSION INQUIRY WRITTEN—
May 6, 2026RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Aug 4, 2025GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Aug 4, 2025GNSLLETTER OF SUSPENSION E-MAILED—
Aug 4, 2025CNSLSUSPENSION LETTER WRITTEN—
Jul 29, 2025DOCKASSIGNED TO EXAMINER—
Jul 28, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 14, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance